Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001193125-23-011491
Filing Date
2023-01-20
Accepted
2023-01-20 07:59:00
Documents
8
Period of Report
2023-01-20

Document Format Files

Seq Description Document Type Size
1 FORM 6-K d367807d6k.htm 6-K 10213
2 EX-99.1 d367807dex991.htm EX-99.1 82184
3 EX-99.2 d367807dex992.htm EX-99.2 8939
4 GRAPHIC g367807dsp015.jpg GRAPHIC 130541
5 GRAPHIC g367807dsp016.jpg GRAPHIC 209722
6 GRAPHIC g367807dsp017.jpg GRAPHIC 167833
7 GRAPHIC g367807g04q07.jpg GRAPHIC 8644
8 GRAPHIC g367807sp5.jpg GRAPHIC 1829
  Complete submission text file 0001193125-23-011491.txt   817404
Mailing Address THREE INTERNATIONAL TOWERS LEVEL 24, 300 BARANGAROO AVENUE SYDNEY NSW C3 2000
Business Address THREE INTERNATIONAL TOWERS LEVEL 24, 300 BARANGAROO AVENUE SYDNEY NSW C3 2000 01161298780088
KAZIA THERAPEUTICS LTD (Filer) CIK: 0001075880 (see all company filings)

EIN.: 000000000 | Fiscal Year End: 0630
Type: 6-K | Act: 34 | File No.: 000-29962 | Film No.: 23538925
SIC: 2834 Pharmaceutical Preparations